Skip to content

Cerus CERS Free cash flow yield

Free cash flow yield at other companies

CorMedix logo
CorMedixCRMD
36.3%+33.4pp
Haemonetics logo
HaemoneticsHAE
9.9%+5.5pp
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
4.7%-0.5pp
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-12.1%-4.1pp
ADMA Biologics logo
ADMA BiologicsADMA
5%+3.1pp
Paysign logo
PaysignPAYS
23.3%

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total debt$45.0M-43.3%
Total equity$67.6M+21.7%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%
Free cash flow-$3.3M-243%

Valuation

See full
Market cap$573.06M+124%
Enterprise value$590.17M+86.7%
P/S2.9×-1.0×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Calculated from Cerus’s reported figures.

Based on trailing twelve months.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cerus's free cash flow yield?
Cerus (CERS) reported free cash flow yield of -0.3% in Q1 2026.
How has Cerus's free cash flow yield changed year-over-year?
Cerus's free cash flow yield decreased by 113.4% year-over-year, from 2.6% to -0.3%.
What is the long-term trend for Cerus's free cash flow yield?
Over 5 years (2020 to 2025), Cerus's free cash flow yield has grown at a -40.1% compound annual growth rate (CAGR), from -3.6% to 0.3%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.